A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: JNJ-80948543
DRUG: JNJ-75348780

Sponsor

Janssen Research & Development, LLC